Home » Celator Pharma Initiates Clinical Study in Patients With Untreated MDS/AML
Celator Pharma Initiates Clinical Study in Patients With Untreated MDS/AML
August 16, 2013
Celator is enrolling patients in a trial to test CPX-351 injections for patients with untreated high-risk myelodysplastic syndrome or acute myeloid leukemia.
Pharmabiz.com
Pharmabiz.com
Upcoming Events
-
21Oct